( EuronextParis:SAN,NYSE:SNY )

News from Sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 08, 2017, 07:30 ET Sanofi Delivers 2016 Sales and Business EPS Growth at CER

Sanofi (NYSE: SNY; EURONEXT: SAN) Q4 2016 Change Change (CER) 2016...


Feb 08, 2017, 03:05 ET Sanofi - Interview du Directeur Général - Résultats 2016 (vidéo)

Sanofi, un leader mondial et diversifié de la santé, publie ses résultats pour l'année 2016. Le Directeur Général du Groupe, Olivier Brandicourt,...


Feb 08, 2017, 03:02 ET Sanofi CEO Interview - FY 2016 Results (video)

Sanofi, a global and diversified healthcare leader, reports results for 2016. Olivier Brandicourt, Chief Executive Officer of Sanofi, comments on...


Feb 01, 2017, 08:00 ET Sanofi's Xyzal® Allergy 24HR Approved for Over-the-Counter Use in the United States

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the...


Jan 09, 2017, 08:00 ET Sanofi and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune Diseases

Sanofi and ImmuNext, Inc., announced today an agreement focused on the development of a novel antibody with the potential to treat a range...


Jan 04, 2017, 08:00 ET Sanofi Announces Soliqua™ 100/33 Now Available in the U.S.

Sanofi announced today that Soliqua™ 100/33 (insulin glargine 100 Units/mL & lixisenatide* 33 mcg/mL injection) is now available by...


Dec 12, 2016, 12:29 ET Scottish Medicines Consortium Approves Sanofi Prostate Cancer Drug

Jevtana® (cabazitaxel) for Men With Metastatic Hormone-refractory Prostate Cancer Accepted for Routine use in NHS Scotland Sanofi Genzyme, the...


Nov 21, 2016, 19:19 ET Sanofi Receives FDA Approval of Soliqua™ 100/33 for the Treatment of Adults with Type 2 Diabetes

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved once-daily Soliqua™ 100/33 (insulin glargine & lixisenatide...


Nov 17, 2016, 16:01 ET New Survey Finds Men in the U.S. Want to Take Charge of Their Own Health and Wellness

A new survey reveals that 90% of men in the U.S. want to take charge of their own health. The U.S. is one of eight countries that participated in...


Oct 28, 2016, 08:14 ET Sanofi Announces Strong Q3 2016 Results

Sanofi (NYSE: SNY; EURONEXT: SAN) Q3 2016 Change Change (CER)...


Oct 28, 2016, 03:43 ET Sanofi - Interview du Directeur Financier - Résultats T3 2016 (vidéo)

Sanofi, un leader mondial et diversifié de la santé, publie ses résultats pour le troisième trimestre 2016. Le Directeur Financier du Groupe,...


Oct 28, 2016, 03:42 ET Sanofi CFO Interview - Q3 2016 Results (Video)

Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2016. Jérôme Contamine, Chief Financial Officer of...


Oct 05, 2016, 08:30 ET New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease

 A new survey of 505 American adults (18 years of age and older) who self-reported being diagnosed with moderate-to-severe atopic dermatitis...


Sep 12, 2016, 08:04 ET Sanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform

Sanofi and Verily Life Sciences LLC, (formerly Google Life Sciences), an Alphabet company, today announced the launch of Onduo, a joint...


Jul 29, 2016, 08:00 ET Sanofi Announces Q2 2016 Results

 Sanofi (NYSE: SNY; EURONEXT: SAN) Experience the interactive Multimedia News Release here:...


Jul 29, 2016, 01:49 ET VIDEO : Sanofi - Résultats T2 2016 Interview de Olivier Brandicourt, Directeur Général

Sanofi, un leader mondial et diversifié de la santé, publie ses résultats pour le deuxième trimestre 2016. Le Directeur...


Jul 29, 2016, 01:46 ET VIDEO: Sanofi - Q2 2016 Results Interview with CEO Olivier Brandicourt

Sanofi, a global and diversified healthcare leader, reports results for the second quarter of 2016. CEO Olivier Brandicourt comments on the...


Jul 27, 2016, 20:12 ET Sanofi Receives FDA Approval of Adlyxin™ for Treatment of Adults with Type 2 Diabetes

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Adlyxin™ (lixisenatide), a once-daily mealtime GLP-1...


Jul 12, 2016, 07:00 ET Award-Winning Chef Elizabeth Falkner Reveals Her Struggle with Atopic Dermatitis to Highlight the Physical and Psychological Impact of the Disease

 Celebrity chef, restaurateur, and media personality Elizabeth Falkner has teamed up with Sanofi Genzyme, Regeneron Pharmaceuticals, Inc., the...


Jun 12, 2016, 15:54 ET Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

 Sanofi announced today the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational...


Jun 11, 2016, 11:01 ET Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting

 Sanofi announced today the release of the new real world data assessing the use of Toujeo® (insulin glargine injection 300 Units/mL). The...


May 25, 2016, 18:50 ET FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes

 Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA)...


Apr 29, 2016, 07:37 ET Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates

 Sanofi (NYSE: SNY; EURONEXT: SAN) Experience the interactive Multimedia News Release here:...


Apr 29, 2016, 05:07 ET Sanofi Q1 2016 Results

Sanofi, a global and diversified healthcare leader, reports results for the first quarter of 2016. Jérôme Contamine,...


Apr 29, 2016, 04:54 ET Sanofi - Résultats T1 2016

Interview de Jérôme Contamine, Directeur Financier Sanofi, leader mondial et diversifié de la santé, publie ses...